|Bid||218.16 x 1200|
|Ask||218.68 x 800|
|Day's Range||217.44 - 226.76|
|52 Week Range||203.37 - 460.21|
|Beta (5Y Monthly)||1.27|
|PE Ratio (TTM)||26.50|
|Earnings Date||Aug 02, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||327.64|
Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.
It is hard to get excited after looking at Charles River Laboratories International's (NYSE:CRL) recent performance...
WILMINGTON, Mass. & MACCLESFIELD, England, June 28, 2022--Charles River announces the opening of their High Quality Plasmid DNA Centre of Excellence at Bruntwood SciTech’s Alderley Park.